This is the authors' abstract. We don't add key points for this paper.
Amphotericin B is the only broad-spectrum antifungal agent currently available for the treatment of systemic mycotic infections in man. Administered intravenously, it has been effective in the treatment of patients with histoplasmosis, North American blastomycosis, coccidiomycosis, cryptococcosis, and specific Candida infections. In addition, isolated cases of South American blastomycosis, aspergillosis, sporotrichosis, mucormycosis, and chromoblastomycosis have responded favorably. Intrathecal administration is frequently indicated in systemic fungal infections involving the central nervous system. The reversible side effects of chills, fever, nausea, vomiting, hypokalemia, anemia, and azotemia warrant necessary precautions during the administration of this agent. Simple safeguards can effectively control these manifestations and so enhance the usefulness of this potent antifungal antibiotic when used via the intravenous and intrathecal routes.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Vincent T. Andriole (1962) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: